Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Filing Date: August 31, 2018
Reporting Period: Six months ended June 30, 2018
Context: This filing incorporates by reference a press release and unaudited interim condensed consolidated financial statements announcing financial results and updates on drug development programs.
Key Financial Metrics
The provided text serves as a cover sheet and exhibit index. It does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the incorporated exhibits (Exhibit 99.1 and Exhibit 99.2) which are not included in the input text.
Material Changes
The filing text does not provide specific data to compare current period performance against prior comparable periods. Material changes regarding financial results and drug development updates are detailed in the incorporated press release (Exhibit 99.3).
Guidance, Outlook, and Risks
The filing incorporates "Forward Looking Statements" and an "Operating and Financial Review and Prospects" (Exhibit 99.1) by reference. The text confirms the company issued updates on its drug development programs but does not detail specific guidance, risks, or contingencies within the cover document itself.
Investor Verification Checklist
- Review Exhibit 99.1 for the detailed Operating and Financial Review and Prospects.
- Examine Exhibit 99.2 for the unaudited interim condensed consolidated financial statements to verify cash position and burn rate.
- Read Exhibit 99.3 (Press Release) for specific drug development updates and forward-looking statements.
- Confirm the incorporation of these exhibits into the Company's Registration Statements on Form F-3.